- Home
- SGHT vs CMPS Comparison
SGHT vs CMPS Comparison
Compare SGHT & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- CMPS
- Stock Information
- Founded
- SGHT 2011
- CMPS 2020
- Country
- SGHT United States
- CMPS United Kingdom
- Employees
- SGHT N/A
- CMPS N/A
- Industry
- SGHT Medical Specialities
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- SGHT Health Care
- CMPS Health Care
- Exchange
- SGHT Nasdaq
- CMPS Nasdaq
- Market Cap
- SGHT 304.4M
- CMPS 280.2M
- IPO Year
- SGHT 2021
- CMPS 2020
- Fundamental
- Price
- SGHT $3.54
- CMPS $4.00
- Analyst Decision
- SGHT Buy
- CMPS Strong Buy
- Analyst Count
- SGHT 7
- CMPS 6
- Target Price
- SGHT $6.27
- CMPS $33.60
- AVG Volume (30 Days)
- SGHT 234.0K
- CMPS 705.9K
- Earning Date
- SGHT 11-07-2024
- CMPS 10-31-2024
- Dividend Yield
- SGHT N/A
- CMPS N/A
- EPS Growth
- SGHT N/A
- CMPS N/A
- EPS
- SGHT N/A
- CMPS N/A
- Revenue
- SGHT $79,543,000.00
- CMPS N/A
- Revenue This Year
- SGHT $2.18
- CMPS N/A
- Revenue Next Year
- SGHT $8.14
- CMPS N/A
- P/E Ratio
- SGHT N/A
- CMPS N/A
- Revenue Growth
- SGHT N/A
- CMPS N/A
- 52 Week Low
- SGHT $3.16
- CMPS $3.86
- 52 Week High
- SGHT $8.45
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- SGHT 36.40
- CMPS 37.40
- Support Level
- SGHT $3.52
- CMPS $3.86
- Resistance Level
- SGHT $3.73
- CMPS $4.91
- Average True Range (ATR)
- SGHT 0.20
- CMPS 0.28
- MACD
- SGHT 0.01
- CMPS -0.01
- Stochastic Oscillator
- SGHT 24.54
- CMPS 16.59
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.